SCHEMBL15065053

SCHEMBL15065053

CCCCCCC(C)c1cc(-c2cc(C(C)CCCCCC)cc(C(C)(C)C)c2O)c(O)c(C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
GPR84 Q9NQS5 1/20 0.38
F2R P25116 1/20 0.35
NR5A2 O00482 1/20 0.35
NR5A1 Q13285 1/20 0.35
KDR P35968 1/20 0.34
CA2 P00918 2/20 0.34
CA1 P00915 1/20 0.34
ADRB2 P07550 4/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
TSHR P16473 1/20 0.34
IDH1 O75874 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
POLB P06746 1/20 0.33
TYR P14679 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15064911 0.98 CYP1A2 (0.39) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL15064994 0.94 CYP1A2 (0.40) CYP1A2CYP2D6F2RNR5A2NR5A1
SCHEMBL28045345 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL3117187 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL11848726 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL11805953 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL10775543 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL10774687 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL14976954 0.92 CA2 (0.41) CYP1A2CYP2D6GPR84F2RNR5A2
SCHEMBL10081832 0.91 CA2 (0.42) CYP1A2CYP2D6GPR84NR5A2NR5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797938-B1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2016-06-01 EP disclosed
EP-2797938-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2014-11-05 EP disclosed
US-8841474-B2 Process for preparing 6-chlorodibenzo[D,F][1,3,2]dioxaphosphepin BASF SE (DE) 2014-09-23 US disclosed
WO-2013098371-A1 METHOD FOR PRODUCING 6-CHLORODIBENZO [D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 WO disclosed
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN BASF SE (DE) 2013-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172596-A1 PROCESS FOR PREPARING 6-CHLORODIBENZO[D,F][1,3,2]DIOXAPHOSPHEPIN DCPS, PLCB3, DDT CYP1A2 1559/4885CYP2D6 98/4885GPR84 4724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.